Am J Transplant, Volume 20, Suppl 3 Archives - Page 92 of 223 - ATC Abstracts

2020 American Transplant Congress
Cancer Risk in Living Kidney Donors (LKDs) in the United States
E. Engels¹, K. Yu¹, S. Brown¹, K. Pawlish², C. Lynch³, B. Kasiske⁴, J. Snyder⁴, R. Pfeiffer¹
¹National Cancer Institute, Bethesda, MD, ²New Jersey Dept of Health, Trenton, NJ, ³Univ of Iowa, Iowa City, IA, ⁴Scientific Registry of Transplant Recipients, Minneapolis, MN
*Purpose: Individuals who wish to donate a kidney for transplantation are evaluated for transmissible diseases (including cancer) prior to donation. Outcomes in LKDs after donation…
2020 American Transplant Congress
Treatment of BK Viremia in Kidney Transplant Recipients: A Single-Center Experience
M. Chaung, E. Hollinger, M. Brokhof, N. Kenyon, L. Lineberger, N. Alvey
Rush University Medical Center, Chicago, IL
*Purpose: Over the past 10 years, our center has utilized various strategies in managing BK viremia in our kidney transplant recipients. Reducing immunosuppression (IMS) in…
2020 American Transplant Congress
Report of Organ Offers Linked with Instant Messaging Data Provides a Basis for Quality Improvement
E. Pahl
Health Informatics, University of Iowa, Iowa City, IA
*Purpose: Thousands of viable organs are discarded every year with incorrect or inappropriate reasons for declination. One limitation on the accessibility of organ transplantation is…
2020 American Transplant Congress
Medication Knowledge Retention and Adherence Following Transplant: Is There Room for Improvement?
M. H. Cooper¹, A. W. Rogers¹, T. L. Menser², J. C. Krisl¹
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX
*Purpose: Transplant recipients’ complex medication regimens following transplant can lead to non-adherence, which has been linked to increased rates of acute rejection and graft loss.…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Combined Heart-Liver Transplantation Has Excellent Long-Term Outcomes
J. A. Steadman¹, J. M. Stulak¹, A. L. Clavell², S. S. Kushwaha², B. S. Edwards², N. L. Pereira², B. A. Boilson², A. Behfar², R. J. Rodeheffer², J. A. Dearani¹, T. Taner³, R. C. Daly¹
¹Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²Division of Cardiovascular Disease, Mayo Clinic, Rochester, MN, ³Division of Transplantation Surgery, Mayo Clinic, Rochester, MN
*Purpose: Combined heart-liver transplants (CHLTx) have been shown to have good short-term outcomes in those with end-stage heart and liver disease: we conducted a comprehensive…
2020 American Transplant Congress
Transpulmonary Gradient as a Predictor for Outcomes after Single Lung Transplantation in Patients with Pulmonary Hypertension
A. Madde¹, E. Chan², J. Ryan², P. Reck Dos Santos², M. Morrell³, J. Luketich², P. Sanchez²
¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²UPMC Department of Cardiothoracic Surgery, Pittsburgh, PA, ³UPMC Division of Pulmonary Medicine, Pittsburgh, PA
*Purpose: End stage lung disease is commonly associated with pulmonary artery hypertension (PAH). In a donor restrictive environment, offering patients single over double lung transplants…
2020 American Transplant Congress
Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury
P. Chung¹, K. Forrester², S. Ganesh¹
¹Division of Pulmonary Critical and Sleep Medicine, University of Southern California, Los Angeles, CA, ²Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA
*Purpose: Mycophenolate mofetil (MMF) is one of the main immunosuppressive medications given in lung transplantation (LTx). It is given orally (PO) or intravenously (IV). In…
2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
O. Pankewycz¹, M. Laftavi¹, E. Onan², D. Rucker¹, D. Wang¹, K. Bhuta¹, R. Gruessner³, A. Gruessner³
¹SUNY, Upstate Medical University, Syracuse, NY, ²Cukurova University, Adana, Turkey, ³SUNY, Downstate Medical University, New York, NY
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…
2020 American Transplant Congress
An Immune-Modulatory Strategy to Mitigate Hepatic Ischemia Reperfusion/Injury in a Murine Model
A. Kobayashi¹, A. Wanchoo², J. Simonovich², S. Duarte¹, V. Boominathan¹, S. Shrestha¹, G. Hudalla², B. Keselowsky²
¹Surgery, University of Florida, Gainesville, FL, ²Biomedical Engineering, University of Florida, Gainesville, FL
*Purpose: Hepatic ischemia/reperfusion injury (IRI) is the leading cause of early graft dysfunction and contributes to the shortage of donor organs. However, despite its obvious…